These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
524 related articles for article (PubMed ID: 17947462)
1. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462 [TBL] [Abstract][Full Text] [Related]
2. Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways. Berg D; Stühmer T; Siegmund D; Müller N; Giner T; Dittrich-Breiholz O; Kracht M; Bargou R; Wajant H FEBS J; 2009 Dec; 276(23):6912-27. PubMed ID: 19895579 [TBL] [Abstract][Full Text] [Related]
3. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents. Sors A; Jean-Louis F; Bégué E; Parmentier L; Dubertret L; Dreano M; Courtois G; Bachelez H; Michel L Clin Cancer Res; 2008 Feb; 14(3):901-11. PubMed ID: 18245554 [TBL] [Abstract][Full Text] [Related]
5. The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Khong T; Sharkey J; Spencer A Haematologica; 2008 Jun; 93(6):860-9. PubMed ID: 18443271 [TBL] [Abstract][Full Text] [Related]
6. Caspase-mediated p65 cleavage promotes TRAIL-induced apoptosis. Kim HS; Chang I; Kim JY; Choi KH; Lee MS Cancer Res; 2005 Jul; 65(14):6111-9. PubMed ID: 16024612 [TBL] [Abstract][Full Text] [Related]
7. Antimyeloma effects of a sesquiterpene lactone parthenolide. Suvannasankha A; Crean CD; Shanmugam R; Farag SS; Abonour R; Boswell HS; Nakshatri H Clin Cancer Res; 2008 Mar; 14(6):1814-22. PubMed ID: 18347184 [TBL] [Abstract][Full Text] [Related]
8. Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Braeuer SJ; Büneker C; Mohr A; Zwacka RM Mol Cancer Res; 2006 Oct; 4(10):715-28. PubMed ID: 17050666 [TBL] [Abstract][Full Text] [Related]
9. Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. Jourdan M; Moreaux J; Vos JD; Hose D; Mahtouk K; Abouladze M; Robert N; Baudard M; Rème T; Romanelli A; Goldschmidt H; Rossi JF; Dreano M; Klein B Br J Haematol; 2007 Jul; 138(2):160-8. PubMed ID: 17542984 [TBL] [Abstract][Full Text] [Related]
10. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma. Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273 [TBL] [Abstract][Full Text] [Related]
11. Resistance of melanoma cells to TRAIL does not result from upregulation of antiapoptotic proteins by NF-kappaB but is related to downregulation of initiator caspases and DR4. Kurbanov BM; Fecker LF; Geilen CC; Sterry W; Eberle J Oncogene; 2007 May; 26(23):3364-77. PubMed ID: 17160022 [TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Hideshima T; Chauhan D; Hayashi T; Podar K; Akiyama M; Mitsiades C; MItsiades N; Gong B; Bonham L; de Vries P; Munshi N; Richardson PG; Singer JW; Anderson KC Cancer Res; 2003 Dec; 63(23):8428-36. PubMed ID: 14679006 [TBL] [Abstract][Full Text] [Related]
14. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572 [TBL] [Abstract][Full Text] [Related]
15. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700 [TBL] [Abstract][Full Text] [Related]
16. 1'-Acetoxychavicol acetate induces apoptosis of myeloma cells via induction of TRAIL. Ito K; Nakazato T; Murakami A; Ohigashi H; Ikeda Y; Kizaki M Biochem Biophys Res Commun; 2005 Dec; 338(4):1702-10. PubMed ID: 16289031 [TBL] [Abstract][Full Text] [Related]
17. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway. Wang X; Ju W; Renouard J; Aden J; Belinsky SA; Lin Y Cancer Res; 2006 Jan; 66(2):1089-95. PubMed ID: 16424045 [TBL] [Abstract][Full Text] [Related]
18. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102 [TBL] [Abstract][Full Text] [Related]
19. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641 [TBL] [Abstract][Full Text] [Related]
20. Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis. Chen H; Li M; Campbell RA; Burkhardt K; Zhu D; Li SG; Lee HJ; Wang C; Zeng Z; Gordon MS; Bonavida B; Berenson JR Oncogene; 2006 Oct; 25(49):6520-7. PubMed ID: 16702955 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]